Trial reportDrug design, development and therapy2026
Determination of the ED50 of Tegileridine and Comparison with Fentanyl for Analgesia During Hysteroscopy in Chinese Female Patients: An Exploratory Sequential Dose‑Finding Study.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Tegileridine is a novel selective μ-opioid receptor agonist. This exploratory dose‑finding study aimed to estimate the 50% effective dose (ED50) and secondarily the 95% effective dose (ED95) of tegileridine for suppressing the cervical dilation reflex during hysteroscopic surgery under propofol anesthesia, compare it with fentanyl, and evaluate perioperative safety in an exploratory manner. Methods: This prospective, randomized, single‑center trial enrolled 54 patients (ASA I‑II). Patients received tegileridine (initial dose 16.67 μg/kg) or fentanyl (initial dose 2 μg/kg) with propofol. Doses were adjusted using the Dixon sequential method. The primary endpoint was ED50 with its 95% confidence interval (CI), estimated using the percentile bootstrap method (2,000 replicates) as the primary inferential framework. ED95 was calculated secondarily via probit regression. Safety data are reported descriptively. Results: Twenty‑seven patients per group completed the study. The bootstrap‑based ED50 for tegileridine was 23.22 μg/kg (95% CI: 22.39‑24.19); for fentanyl, 1.51 μg/kg (95% CI: 0.97‑4.07). The ED50 potency ratio (tegileridine:fentanyl) was approximately 1:15 (95% uncertainty range derived from bootstrap CIs: 1:5.5 to 1:24.9). The ED95 values from probit regression were 23.89 μg/kg (95% CI: 23.68‑24.12) for tegileridine and 1.97 μg/kg (95% CI: 1.87‑2.07) for fentanyl. Respiratory depression/hypoxemia was observed in 14.8% of the tegileridine group and 59.3% of the fentanyl group; these exploratory findings should be interpreted with caution given the small sample and open‑label design. Conclusion: This exploratory study estimated the ED50 of tegileridine and fentanyl for hysteroscopic surgery. The ED50-based potency ratio and the observed differences in safety outcomes require confirmation in larger, adequately powered, blinded trials. The ED95 estimates are model‑based and carry substantial uncertainty. Trial Registration: Chinese Clinical Trial Registry, ChiCTR2500107995.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.